Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Investor Presentation (September 2015)

27 slides from Acer Therapeutics's investor presentation, Sep 2, 2015

  1. Slide 1: Precision Immunotherapy

    Precision Immunotherapy®

  2. Slide 2: Forward-Looking Statements

    oe ‘OPEXA Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our preclinical and clinical development plans for Teelna® and OPX-212, our research and other development programs, our ability to undertake certain activitie

  3. Slide 3: Opexa Investment Highlights

    oe ‘OPEXA Opexa Investment Highlights > PIPELINE + Teeina®: Phase 2b for secondary progressive multiple sclerosis (SPMS), limited competition, $7BN overall market potential + OPX-212: Pre-IND for neuromyelitis optica (NMO), no approved therapies, orphan indication » TECHNOLOGY + Personalized T-cell

  4. Slide 4: Recent and Upcoming Expected Milestones

    oe ‘OPEXA Recent and Upcoming Expected Milestones Tcelna: Multiple Sclerosis Y 1H 2014: Completed Enrollment in Phase 2b SPMS trial Y Qu 2015: Received additional $3M payment from Merck Serono for Tcelna development Y Qg 2015: 85% of all patient visits in Abili-T trial have been completed + 2H 2016:

  5. Slide 5: Financials

    oe ‘OPEXA Financials Cash and Cash Equivalents (MM) as of June 30, 2015 ~$18.3 Shares outstanding (MM) as of June 30, 2015 ~53.4 Warrants (MM) outstanding as of June 30, 2015 ~28.4 Stock Options (MM) outstanding as of June 30, 2015, ~3.3 Debt None (4) Weighted average exercise price =$.80 as of June

  6. Slide 6: Opexa's Novel Approach; Priming the Immune System

    OPEXA’S NOVEL APPROACH; PRIMING THE IMMUNE SYSTEM

  7. Slide 7: Root cause of MS: Activated T-cells degrade myelin and damage myelin producing cells

    @ ove riceavcvnes Root cause of MS: Activated T-cells degrade myelin and damage myelin producing cells In MS patients, the faulty immune system is not able to prevent the attack of a small sub- population of myelin reactive T-cells (MRTC) MRTCs cross the blood brain barrier, enter the brain, and bin

  8. Slide 8: Tcelna could address the root cause of MS by preventing demyelination

    @ over rnewarcuncs Tcelna could address the root cause of MS by preventing demyelination and enabling remyelination “Acapted by permission from Macmilan Pubishecs Lis. WATURE REVEWS ‘MGnoLdey 542-492 (ne 2009), copy 2005) + Therapeuticdose of Teena (attenuated T-cell clones) is injected subcutaneous

  9. Slide 9: ImmPath manufacturing platform

    ImmPath® manufacturing platform 14 days 35 days aiday Epitope Profiling Manufacturing and QC Dispensation } - Red Cross ——— a —— . y iia & ~lEga- Bes EpitopeProfiling __ Expansion of antigen specific T-cells Formulation/ Administration: 5 pay namie each dose as injections/year irse of treatment

  10. Slide 10: Clinical evidence for Tcelna MoA

    Clinical evidence for Tcelna MoA ‘T-cell technology demonstrated a significant reduction in reactive T-cells (52 week study results of MS) Reduction in MRTC Week o Week Week 13 Week 21 Week 28 Week 52 0% Dose 4 30% 40% 50% 60% 10% 80% ars + Results from Teelna dose ranging studies: 1” Published n Cl

  11. Slide 11: Phase 2b RRMS prior clinical trial

    Phase 2b RRMS prior clinical trial @ orem mrrons Toelna showed 37% improvement over placebo (mITT) (secondary endpoint measurement, primary MRI endpoint measure not met) 37% Reduction in Annualized Relapse Rate (ARR) 04 0.35 0-339 37% aTcelna = Placebo n=142 Relapses/Patient/Year 0.05 — a8 Total mIT

  12. Slide 12: ImmPath: Opexa's Proprietary T-Cell Immunotherapy Platform

    IMMPATH®: OPEXA’S PROPRIETARY T-CELL IMMUNOTHERAPY PLATFORM

  13. Slide 13: Leveraging ImmPath platform in new indications

    @ ove ricesvevnes Leveraging ImmPath® platform in new indications ImmPath®: Personalized, Precision Immunotherapy Platform Preclinical Potential New Targets: Neuromyelitis in diseases with known antigen profile i . vowtes optica Secondary Progressive © Adiotyass Uireenbaatonene mapas Multiple Sclero

  14. Slide 14: Expansion of Pipeline Increases Opportunity

    Expansion of Pipeline Increases Multiple Sclerosis + Quick access to market Japan + Leverage US. trial success Autoimmune + Development stage programs diseases with —) ~ i.e. OPX-212 for NMO known antigens + Orphan disease benefits Autoimmune + Discovery stage programs diseases with —— _ + Possible

  15. Slide 15: Tcelna for Multiple Sclerosis

    TCELNA® FOR MULTIPLE SCLEROSIS

  16. Slide 16: Tcelna in Secondary Progressive MS

    oe OPEXA THERAPEUTICS Tcelna in Secondary Progressive MS 450,000 Individuals in North America diagnosed with M. 30-45 % potentially have an SPMS diagnosis + Secondary Progressive MS market potential in North America could exceed $7 billion (for all therapies) + Roughly 150,000 SPMS patients in North

  17. Slide 17: Tcelna: Lead Program Targeting Secondary Progressive MS

    Tcelna® Lead Program Targeting Secondary Progressive MS patients Fast Track Designation by FDA + Phase 2b is fully enrolled: 190 patients with SPMS + Top line data expected in 2H 2016 + Design = Double-blind, 1:1 randomized, placebo-controlled — 35 clinical sites in USA and Canada = Two annual cours

  18. Slide 18: Merck Serono Agreement

    oe ‘OPEXA Merck Serono Agreement Agreement signed 2013; strong potential partner + Option and License Agreement for worldwide rights to all Multiple Sclerosis indications, excluding Japan + If Merck Serono exercises option: — Merck Serono to fund Phase 3, pre-commercial and commercial activities — O

  19. Slide 19: Leveraging the T-Cell Platform: OPX-212 for Neuromyelitis Optica

    LEVERAGING THE T-CELL PLATFORM: OPX-212 FOR NEUROMYELITIS OPTICA (NMO)

  20. Slide 20: NMO: A rare disease of the Central Nervous System

    @ om NMO: A rare disease of the Central Nervous System + Neuromyelitis optica (NMO) isa rare or orphan autoimmune disease + Immune system cells and antibodies mistakenly attack and destroy myelin cells in the opticnerves and the spinal cord + Individuals with NMO develop optic neuritis, which causes

  21. Slide 21: Key Milestones Achieved to Date in OPX-212 Development Program

    onexa Key Milestones Achieved to Date in OPX-212 Development Program Funding support + Recently secured $5 million private funding for OPX-212 to advance further NMO development, including Phase I/II clinical study KOL support + Engaged key thought leaders to validate scientific hypothesis and discu

  22. Slide 22: NMO disease pathogenesis

    GB overs thewarcuncs NMO disease pathogenesis - <_ —P CD4+ TeellcDs9 _nflration of ‘racrophagesand Acttvated T-cell Th-ir granulocytes ‘AQP4 antibodies thatpenetrate Binding 4076 thecsSandbinato ges camisonde channelson theastrocyte astrocytes EET Complement if = activation ae & nerease astrocyte pe

  23. Slide 23: Potential intervention points for T-cell therapy

    OPEXA THERAPEUTICS Potential intervention points for T-cell therapy T-cell therapy believed to inhibit AQP-4 autoantibody, pro-inflammatory cytokines and prevent infiltration of macrophages and granulocytes [opx-ai2 | * = eetnencsinae ee 7 eee en 1 — eesti CS ee a ae ) production of the AQP-4 antibo

  24. Slide 24: NMO Investment Thesis

    oe ‘OPEXA NMO Investment Thesis + Any therapy that could achieve tolerization of the AQP-4 reactive T- cells may offer a cure for NNO * OPX-212 has the potential to address the root cause of NNO * OPX-212 leverages Opexa’s T-cell platform to B-cell mediated orphan diseases * Opexa currently retains

  25. Slide 25: Experienced Management Team and Board of Directors

    GD over rexarcunc Experienced Management Team and Board of Directors ‘Neil Warma, President & CEO, Director > 19% years intemational healthcare experience with large Pharma and emergin otedhnology companies ae ee ae > Former Senior Management, Novartis Pharmaceuticals, Basel, Switzerland > Former CE

  26. Slide 26: SPMS Scientific Advisory Board

    oe ‘OPEXA SPMS Scientific Advisory Board > v Dawn McGuire, M.D., FAAN (Chair) + Advisory Council of the Gill Heart Institute + Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D + Chair of Neurology at Heinrich-Heine University, Diisseldorf + Executive Board m

  27. Slide 27: Opexa Investment Thesis

    oe ‘OPEXA Opexa Investment Thesis TECHNOLOGY + Proprietary Platform: potential to yield multiple drug candidates + Differentiated, personalized approach + Strong patent estate (98 domestic and international) PIPELINE + Tcelna: Secondary Progressive MS, limited competition, $7BN potential market + OP

Opexa Therapeutics — Investor Presentation (September 2015) on 6ix